These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37871699)

  • 1. Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups.
    Wong NZH; Yap DWT; Ong RJM; Zhao JJ; Chan YH; Tey JCS; Sundar R; Lim JSJ; Dawood SS
    Ann Oncol; 2023 Oct; ():. PubMed ID: 37871699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options.
    Wang Y; Tang SC
    Cancer Metastasis Rev; 2022 Dec; 41(4):975-990. PubMed ID: 36229710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date.
    Varella L; Cristofanilli M
    Onco Targets Ther; 2023; 16():189-196. PubMed ID: 36993871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
    Dubash TD; Bardia A; Chirn B; Reeves BA; LiCausi JA; Burr R; Wittner BS; Rai S; Patel H; Bihani T; Arlt H; Bidard FC; Kaklamani VG; Aftimos P; Cortés J; Scartoni S; Fiascarelli A; Binaschi M; Habboubi N; Iafrate AJ; Toner M; Haber DA; Maheswaran S
    Breast Cancer Res Treat; 2023 Aug; 201(1):43-56. PubMed ID: 37318638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment.
    Garcia-Fructuoso I; Gomez-Bravo R; Schettini F
    Curr Opin Oncol; 2022 Nov; 34(6):635-642. PubMed ID: 36000362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
    Tolaney SM; Chan A; Petrakova K; Delaloge S; Campone M; Iwata H; Peddi PF; Kaufman PA; De Kermadec E; Liu Q; Cohen P; Paux G; Wang L; Ternès N; Boitier E; Im SA
    J Clin Oncol; 2023 Aug; 41(24):4014-4024. PubMed ID: 37348019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib
    Bardia A; Cortes J; Hurvitz SA; Delaloge S; Iwata H; Shao ZM; Kanagavel D; Cohen P; Liu Q; Cartot-Cotton S; Pelekanou V; O'Shaughnessy J
    Ther Adv Med Oncol; 2022; 14():17588359221083956. PubMed ID: 35309087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
    Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
    JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
    Bidard FC; Kaklamani VG; Neven P; Streich G; Montero AJ; Forget F; Mouret-Reynier MA; Sohn JH; Taylor D; Harnden KK; Khong H; Kocsis J; Dalenc F; Dillon PM; Babu S; Waters S; Deleu I; García Sáenz JA; Bria E; Cazzaniga M; Lu J; Aftimos P; Cortés J; Liu S; Tonini G; Laurent D; Habboubi N; Conlan MG; Bardia A
    J Clin Oncol; 2022 Oct; 40(28):3246-3256. PubMed ID: 35584336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
    Corti C; De Angelis C; Bianchini G; Malorni L; Giuliano M; Hamilton E; Jeselsohn R; Jhaveri K; Curigliano G; Criscitiello C
    Cancer Treat Rev; 2023 Jun; 117():102569. PubMed ID: 37146385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
    Taylor AM; Chan DLH; Tio M; Patil SM; Traina TA; Robson ME; Khasraw M
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011395. PubMed ID: 33886122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups.
    Yap DWT; Leone AG; Wong NZH; Zhao JJ; Tey JCS; Sundar R; Pietrantonio F
    JAMA Oncol; 2023 Feb; 9(2):215-224. PubMed ID: 36480211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer.
    Bardia A; Mayer I; Winer E; Linden HM; Ma CX; Parker BA; Bellet M; Arteaga CL; Cheeti S; Gates M; Chang CW; Fredrickson J; Spoerke JM; Moore HM; Giltnane J; Friedman LS; Chow Maneval E; Chan I; Jhaveri K
    Breast Cancer Res Treat; 2023 Jan; 197(2):319-331. PubMed ID: 36401732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of SERENA-6, a phase III switching trial of camizestrant in
    Turner N; Huang-Bartlett C; Kalinsky K; Cristofanilli M; Bianchini G; Chia S; Iwata H; Janni W; Ma CX; Mayer EL; Park YH; Fox S; Liu X; McClain S; Bidard FC
    Future Oncol; 2023 Mar; 19(8):559-573. PubMed ID: 37070653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role.
    Lloyd MR; Wander SA; Hamilton E; Razavi P; Bardia A
    Ther Adv Med Oncol; 2022; 14():17588359221113694. PubMed ID: 35923930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical value of circulating
    Zhang K; Hong R; Xu F; Xia W; Kaping L; Qin G; Zheng Q; Lu Q; Shi YX; Yuan ZY; Wang S
    Cancer Manag Res; 2018; 10():2573-2580. PubMed ID: 30147360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
    Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
    Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
    Bardia A; Kaklamani V; Wilks S; Weise A; Richards D; Harb W; Osborne C; Wesolowski R; Karuturi M; Conkling P; Bagley RG; Wang Y; Conlan MG; Kabos P
    J Clin Oncol; 2021 Apr; 39(12):1360-1370. PubMed ID: 33513026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.